Holen Sie sich die Stockscreener-App
32.75
0.85%
0.2621
Schlusskurs vom Vortag:
$32.49
Offen:
$32.35
24-Stunden-Volumen:
317.21K
Relative Volume:
0.84
Marktkapitalisierung:
$1.65B
Einnahmen:
$357.71M
Nettoeinkommen (Verlust:
$-20.10M
KGV:
-82.73
EPS:
-0.3959
Netto-Cashflow:
$28.67M
1W Leistung:
-0.89%
1M Leistung:
-11.28%
6M Leistung:
+9.51%
1J Leistung:
-10.34%
1-Tages-Spanne:
$32.07
$33.10
1-Wochen-Bereich:
$31.37
$33.80
52-Wochen-Spanne:
$23.15
$39.33
Immunocore Holdings Plc Adr Stock (IMCR) Company Profile
Firmenname
Immunocore Holdings Plc Adr
Sektor
Branche
Telefon
01235 5430281
Adresse
90 PARK DRIVE, OXFORDSHIRE
Vergleichen Sie IMCR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMCR
Immunocore Holdings Plc Adr
|
32.76 | 1.63B | 357.71M | -20.10M | 28.67M | -0.3959 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.47 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.94 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
466.36 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
662.79 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
314.35 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunocore Holdings Plc Adr Stock (IMCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-27 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-11-11 | Herabstufung | Mizuho | Outperform → Neutral |
| 2024-10-24 | Eingeleitet | UBS | Sell |
| 2024-10-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-04-29 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-11-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-31 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-13 | Eingeleitet | Needham | Buy |
| 2023-08-16 | Eingeleitet | CapitalOne | Overweight |
| 2023-07-17 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-03-31 | Eingeleitet | Mizuho | Buy |
| 2023-03-30 | Eingeleitet | Guggenheim | Buy |
| 2023-03-24 | Eingeleitet | Bryan Garnier | Buy |
| 2022-12-16 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-30 | Eingeleitet | Barclays | Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-08 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2022-08-08 | Eingeleitet | Cowen | Outperform |
| 2022-08-02 | Eingeleitet | BTIG Research | Buy |
| 2022-02-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-20 | Eingeleitet | Oppenheimer | Outperform |
| 2021-03-02 | Eingeleitet | Goldman | Neutral |
| 2021-03-02 | Eingeleitet | JP Morgan | Overweight |
| 2021-03-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Immunocore Holdings Plc Adr Aktie (IMCR) Neueste Nachrichten
Q3 Earnings Estimate for Immunocore Issued By HC Wainwright - Defense World
FY2027 EPS Estimates for Immunocore Boosted by HC Wainwright - Defense World
Immunocore’s SWOT analysis: stock outlook amid clinical milestones, market challenges - Investing.com
IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi - sharewise.com
PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues - sharewise.com
Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y - Yahoo Finance
Immunocore (IMCR) Q2 Revenue Jumps 30% - The Motley Fool
Compared to Estimates, Immunocore (IMCR) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Immunocore Holdings earnings missed by $0.02, revenue topped estimates - Investing.com South Africa
Perrigo Beats on Q2 Earnings & Sales, Stock Down on '25 Sales View Cut - Yahoo Finance
TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line - sharewise.com
AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y - The Globe and Mail
CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down - Yahoo Finance
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises - Barchart.com
Immunocore to Report Q2 2025 Financial Results on August 7, 2025 - AInvest
Analysts Set Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) PT at $58.89 - Defense World
Wall Street Analysts See a 72.34% Upside in Immunocore (IMCR): Can the Stock Really Move This High? - Yahoo Finance
The IMCR Stock Puzzle: Unraveling Immunocore Holdings plc ADR’s Fluctuating Performance - investchronicle.com
Can Mizuho Financial Group, Inc. ADR Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
Principal Financial Group Inc. Reduces Stock Holdings in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) - Defense World
Immunocore Holdings ADR Earns IBD Rating Upgrade - Investor's Business Daily
MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy - sharewise.com
COGT Stock Soars on Phase III Systemic Mastocytosis Study Success - sharewise.com
5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment - Yahoo Finance
Biogen Begins Phase III Felzartamab Study for Third Kidney Disease - Yahoo Finance
Wall Street Analysts See an 114.35% Upside in Immunocore (IMCR): Can the Stock Really Move This High? - MSN
FDA Grants Label Expansion to AstraZeneca's Datroway in Lung Cancer - Yahoo Finance
FDA Extends INCY's Application for Opzelura Label Expansion - Yahoo Finance
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech - Yahoo Finance
Immunocore’s SWOT analysis: stock outlook amid pipeline progress, market challenges By Investing.com - Investing.com South Africa
Immunocore’s SWOT analysis: stock outlook amid pipeline progress, market challenges - Investing.com India
Brokers Set Expectations for Immunocore FY2026 Earnings - Defense World
GAMMA Investing LLC Boosts Stock Position in Immunocore Holdings plc (NASDAQ:IMCR) - Defense World
Immunocore at Jefferies Global Healthcare Conference: Strong Growth and Promising Trials - Investing.com India
TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises - Yahoo Finance
Wall Street Analysts Think Immunocore (IMCR) Could Surge 65.22%: Read This Before Placing a Bet - sharewise
Deutsche Bank sets $65 target on Immunocore stock, rates Buy - Investing.com
Deutsche Bank sets $65 target on Immunocore stock, rates Buy By Investing.com - Investing.com India
Immunocore’s SWOT analysis: biotech firm’s stock faces challenges amid growth - Investing.com India
Is it a Good Idea to Invest in Immunocore Stock Right Now? - MSN
Balance Sheet Dive: Hippo Holdings Inc (HIPO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Analyzing Ratios: Symbotic Inc (SYM)’s Financial Story Unveiled - DWinneX
New Strong Buy Stocks for May 8th - The Globe and Mail
Immunocore stock rises as Q1 results top estimates By Investing.com - Investing.com South Africa
Immunocore stock rises as Q1 results top estimates - Investing.com
Immunocore Holdings earnings beat by $0.49, revenue topped estimates - Investing.com
Compared to Estimates, Immunocore (IMCR) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down - Barchart.com
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y - The Globe and Mail
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates - Barchart.com
Finanzdaten der Immunocore Holdings Plc Adr-Aktie (IMCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.33%
0.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):